VRC 208: Phase 1/1b Open-Label Clinical Trial to Evaluate Dose, Safety and Immunogenicity of Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine,VRC-EBOMVA079-00-VP, Administered Alone or as Boost to cAd3-Ebola Vaccines in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs GSK 3390107A (Primary) ; VRC-EBOADC069-00-VP (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 07 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Planned End Date changed from 1 Mar 2017 to 22 Jan 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 22 Jan 2018.